Table 1.
Patient Characteristics
| Patient ID | Gender | Ethnicity | Years since diagnosis | Plasma viral load, copies/ml | CSF viral load, copies/ml | CD4 count, cells/μl | CSF WBC, count/mm3 | HIV-specific response studied |
|---|---|---|---|---|---|---|---|---|
| HIV controllers | ||||||||
| EC 7164 | M | C | 20 | <40 | <40 | 740 | 2 | B*5701 Gag KF11 |
| EC 7176 | F | H | 10 | <40 | <40 | 582 | 1 | B*5703 Gag TW10 |
| EC 7178 | F | AA | 18 | <40 | <40 | 1,738 | 7 | n/a |
| EC 7179 | M | C | 22 | <40 | <40 | 535 | 3 | n/a |
| EC 7180 | M | AA | 25 | <40 | <40 | 588 | 6 | n/a |
| EC 7183 | M | C | 25 | <40 | <40 | 731 | 7 | A*0301 Gag RK9 |
| EC 7187 | F | C | 5 | <40 | <40 | 725 | 2 | n/a |
| EC 7191 | M | C | 25 | <40 | <40 | 1,090 | 3 | n/a |
| EC 9038 | M | C | 2 | <40 | <40 | 1,251 | 6 | B*2705 Gag KK10 |
| VC 7190 | M | C | 20 | 231 | <40 | 468 | 1 | B*2705 Gag KK10 |
| VC 7109 | M | AA | 23 | 221 | <40 | 485 | 3 | B*5703 Gag KF11 |
| Noncontrollers | ||||||||
| NC 9012 | M | C | 1.2 | 71,700 | 296 | 544 | 8 | n/a |
| NC 9016 | M | C | 1.1 | 116,000 | 2,380 | 344 | 0 | A*0301 Gag RK9 |
| NC 9036 | M | C | 1.2 | 10,164 | 792 | 590 | 5 | A*0201 Gag SL9 |
| NC 9040 | M | C | 1.75 | 219,377 | 4,415 | 494 | 2 | n/a |
| NC 4141 | M | C | 19 | 62,285 | 63 | 94 | 2 | B*5701 Gag KF11 |
| NC 7193 | M | C | 27 | 15,483 | 11,496 | 396 | 7 | B*2705 Gag KK10 |
| HAART suppressed, n = 7 | 100% M | 5C, 2H | (2–26) | <40 | <40 | (410–917) | (0–4) | n/a |
| Negative controls, n = 9 | 100% M | 7C, 1As, 2AA | n/a | n/a | n/a | (534–1,070) | (0–5) | n/a |
Numbers between parentheses indicate ranges for HAART suppressed and negative controls.
AA, African American; As, Asian; C, Caucasian; CSF, cerebrospinal fluid; EC, elite controllers; H, Hispanic/Latino; n/a, not applicable; NC, noncontrollers; VC, viremic controllers.